ArticleCureus2026
Clear Cell Renal Cell Carcinoma Recurrence Three Decades After Nephrectomy Presenting With New-Onset Diabetes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a common cancer that comprises the majority of all renal cancers. Patients typically present with hematuria, flank pain, and constitutional symptoms like fever, fatigue, and weight loss. ccRCC is often managed with chemotherapy, and, under some circumstances, the removal of a kidney. Although recurrence is possible following removal of the kidney, it is uncommon for a recurrence to occur after several decades. An 80-year-old man with a history of hypertension, hyperlipidemia, and ccRCC status post nephrectomy 33 years prior presented with two months of unintentional weight loss, fatigue, decreased appetite, and urinary frequency. Serial weights confirmed a 24-pound (12%) weight loss. Physical examination was notable only for mild epigastric tenderness. Laboratory evaluation demonstrated new-onset severe hyperglycemia with a hemoglobin A1C of 13.7% and serum glucose of 351 mg/dL, without prior documented diabetes. Given the rapid onset of hyperglycemia and significant weight loss, computed tomography imaging revealed a 9.2 × 6.4 cm pancreatic mass with additional lesions in the right lung and liver, initially concerning for metastatic pancreatic malignancy. Subsequent positron emission tomography and biopsy of the pancreatic head confirmed metastatic ccRCC. The patient was initiated on systemic therapy with axitinib and pembrolizumab, resulting in interval reduction of the pancreatic mass and resolution of pulmonary metastasis on follow-up imaging. Surgical excision of the pancreatic lesion has been scheduled in light of treatment response. This unique presentation and unlikely recurrence illustrate a rare case of ccRCC. Moreso, while diabetes is a known risk factor for ccRCC, the association between ccRCC and new-onset diabetes has rarely been documented. This case seeks to reinforce the importance of considering metastatic disease in patients with unexplained metabolic abnormalities and a remote history of renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.